M&A Deal Summary

Shire Acquires Dyax

On November 2, 2015, Shire acquired life science company Dyax for 5.9B USD

Acquisition Highlights
  • This is Shire’s 14th transaction in the Life Science sector.
  • This is Shire’s 2nd largest (disclosed) transaction.
  • This is Shire’s 12th transaction in the United States.
  • This is Shire’s 4th transaction in Massachusetts.

M&A Deal Summary
Date 2015-11-02
Target Dyax
Sector Life Science
Buyer(s) Shire
Deal Type Add-on Acquisition
Deal Value 5.9B USD
Advisor(s) Centerview Partners (Financial)
Sullivan & Cromwell (Legal)

Target

Dyax

Burlington, Massachusetts, United States
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Shire

Dublin, Ireland
Category Company
Founded 1986
Sector Life Science
Employees5,548
Revenue 6.4B USD (2015)
DESCRIPTION

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

DEAL STATS #
Overall 14 of 16
Sector (Life Science) 14 of 15
Type (Add-on Acquisition) 13 of 14
State (Massachusetts) 4 of 4
Country (United States) 12 of 13
Year (2015) 4 of 4
Size (of disclosed) 2 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-03 Foresight Biotherapeutics

New York, New York, United States

Foresight Biotherapeutics, Inc. is a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye.

Buy $300M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-11 Baxalta

Deerfield, Illinois, United States

Baxalta Incorporated is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.

Buy $32.0B
Mergr

Product

Company

Legal